Abstract
P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have